Bausch Health · conference-presentation
Bausch Health Companies | Results Presentation Deck | 91 slides
91 pages · 4 arc beats · 2 loops
Bausch Health Companies | Results Presentation Deck | 91 slides
Bausch Health · 2021-11 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
15101520253035404550556065707580859091
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 91 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 5 slides 100% 5/5 slides 100% 5/5 slides · 17 hits — 0/5 slides
— 0/5 slides
20% 1/5 slides 100% 5/5 slides — 0/5 slides
Need 10 slides 100% 10/10 slides 100% 10/10 slides · 36 hits — 0/10 slides
20% 2/10 slides 10% 1/10 slides 100% 10/10 slides 100% 10/10 slides Satisfaction 13 slides 100% 13/13 slides 100% 13/13 slides · 77 hits — 0/13 slides
15.4% 2/13 slides 7.7% 1/13 slides 100% 13/13 slides 100% 13/13 slides Action 63 slides 100% 63/63 slides 100% 63/63 slides · 264 hits — 0/63 slides
55.6% 35/63 slides · 36 hits 6.3% 4/63 slides 100% 63/63 slides — 0/63 slides
Slide inventory
91 every slide · same image gating as the playbook
06
Includes a donut chart showing revenue breakdown by segment and key performance metrics.summarize
07
The table includes both reported and organic growth metrics, with footnotes detailing non-GAAP adjustments and segment realignments.analyze_data
08
Includes both GAAP and non-GAAP financial measures with variance analysis.analyze_data
09
Includes a callout box highlighting specific GAAP and non-GAAP cash flow figures.analyze_data
10
Includes footnotes detailing specific debt adjustments and divestiture impacts.analyze_data
11
The slide uses a blue box to visually emphasize the 2021-2024 period with zero debt maturities.summarize
13
Includes detailed assumptions for expenses, tax rates, share counts, and cash items.analyze_data
14
The slide uses a standard waterfall bridge visualization to explain changes in financial guidance.show_valuation_bridge
18
Includes clinical trial data (MOJAVE study) and market opportunity context.summarize
20
The slide uses a mix of bar charts and line charts with trend lines to illustrate recovery.analyze_data
21
Includes a bar chart showing organic growth over time and a bar chart comparing retail prescription growth across products.summarize
22
The slide uses trend lines to highlight recovery and strong performance across three distinct product lines.analyze_data
23
Includes a map-based visualization of regional product performance and a donut chart for revenue breakdown.analyze_data
24
Includes CAGR annotations on bar charts.analyze_data
26
The slide uses a three-column layout to organize leadership bios by company.introduce_nominees
27
Includes product imagery for Solta Medical brands (Thermage, Clear + Brilliant, Fraxel, Vaser).plan_implementation
28
The slide uses a combination of a checklist (left) and a process flow diagram (right) to communicate the deleveraging strategy.plan_implementation
31
The slide uses a grid of icons and metrics to present company fundamentals and market size.summarize
Open slide detailBeat · Action
32
Includes disclaimer about non-retouched photos and medical source credits.illustrate_case
Open slide detailBeat · Action
35
The slide uses a flow diagram to show how business lines were reallocated between two reporting periods.present_framework
Open slide detailBeat · Action
36
The slide details the financial impact of segment realignments, showing reported vs. restated figures.analyze_data
Open slide detailBeat · Action
37
The slide uses a three-column layout to categorize updates by business unit.summarize
Open slide detailBeat · Action
38
The slide uses a grid-based timeline to map four distinct drug development programs against calendar years from 2019 to 2027.plan_implementation
Open slide detailBeat · Action
39
The table tracks financial performance changes for specific product lines following patent expirations.analyze_data
Open slide detailBeat · Action
40
LOE = Loss of Exclusivity. Data shows significant revenue and profit declines across all business units.analyze_data
Open slide detailBeat · Action
41
LOE stands for Loss of Exclusivity. The table tracks financial variance between two forecast periods.analyze_data
Open slide detailBeat · Action
42
The table compares inventory levels across two years, highlighting the change in months on hand for each business unit.analyze_data
Open slide detailBeat · Action
43
The table highlights inventory levels for specific business units, showing an increase in months on hand across all units in the 2021 period compared to 2020.analyze_data
Open slide detailBeat · Action
44
Includes non-GAAP metrics and segment-specific performance data.analyze_data
Open slide detailBeat · Action
45
The slide highlights a 6% organic revenue growth for the Salix segment.analyze_data
Open slide detailBeat · Action
46
The slide highlights a 1% organic revenue decline for the segment.analyze_data
Open slide detailBeat · Action
47
Includes segment-specific revenue and operating expense breakdown.analyze_data
Open slide detailBeat · Action
48
The slide includes a specific callout for the revenue decline of the WELLBUTRIN/APLENZIN product line.analyze_data
Open slide detailBeat · Action
49
Includes detailed footnotes regarding non-GAAP adjustments and constant currency calculations.analyze_data
Open slide detailBeat · Action
50
Includes non-GAAP metrics and segment-specific growth rates.analyze_data
Open slide detailBeat · Action
51
Includes non-GAAP metrics like EBITA and organic growth.analyze_data
Open slide detailBeat · Action
52
Includes non-GAAP metrics like EBITA and organic growth.analyze_data
Open slide detailBeat · Action
53
Includes non-GAAP metrics like EBITA and organic growth.analyze_data
Open slide detailBeat · Action
54
The slide highlights a 7% decline in combined WELLBUTRIN/APLENZIN revenue.analyze_data
Open slide detailBeat · Action
55
Includes footnotes regarding non-GAAP information and constant currency calculations.analyze_data
Open slide detailBeat · Action
56
Includes footnotes regarding non-GAAP information and constant currency calculations.analyze_data
Open slide detailBeat · Action
57
The table tracks revenue in millions of dollars for 10 products across 5 quarters (3Q20 to 3Q21).analyze_data
Open slide detailBeat · Action
58
The table tracks revenue in millions for 10 product lines across 5 quarters (3Q20 to 3Q21).analyze_data
Open slide detailBeat · Action
59
The table lists 10 products with their respective quarterly revenues in millions of dollars.analyze_data
Open slide detailBeat · Action
62
The table lists products by rank and their respective quarterly revenues in millions of dollars.analyze_data
Open slide detailBeat · Action
63
The table reconciles GAAP net income to non-GAAP adjusted net income, detailing specific adjustments like amortization, impairments, and restructuring costs.analyze_data
Open slide detailBeat · Action
64
Includes footnotes regarding non-GAAP adjustments and corporate allocation exclusions.analyze_data
Open slide detailBeat · Action
65
The slide provides supplemental financial metrics for Bausch + Lomb, likely for valuation or segment analysis purposes.analyze_data
Open slide detailBeat · Action
66
The slide contains two distinct tables: one for Revenue and one for EBITA (non-GAAP).analyze_data
Open slide detailBeat · Action
67
The table provides supplemental financial metrics for Bausch Pharma, likely for valuation or modeling purposes.analyze_data
Open slide detailBeat · Action
68
Includes footnotes regarding non-GAAP adjustments and fiscal year reporting.analyze_data
Open slide detailBeat · Action
69
The table provides a detailed breakdown of financial metrics for the International Rx segment, including non-GAAP EBITA.analyze_data
Open slide detailBeat · Action
70
The table breaks down revenue into Ortho Dermatologics and Global Solta components.analyze_data
Open slide detailBeat · Action
71
The table provides a detailed breakdown of financial metrics for the Diversified Products segment, including specific revenue streams (Neuro & Other, Generics, analyze_data
Open slide detailBeat · Action
72
The slide provides a detailed breakdown of non-GAAP adjustments including amortization, asset impairments, restructuring, and other one-time costs.analyze_data
Open slide detailBeat · Action
73
The slide provides a detailed breakdown of non-GAAP adjustments including amortization, impairments, and restructuring costs.analyze_data
Open slide detailBeat · Action
74
Contains footnotes 1-5 explaining segment reporting and asset impairment details.analyze_data
Open slide detailBeat · Action
75
The table reconciles GAAP operating income to non-GAAP by adding back acquisition-related costs and adjustments.analyze_data
Open slide detailBeat · Action
76
The table provides a detailed breakdown of non-GAAP adjustments including asset impairments, restructuring costs, and litigation expenses.analyze_data
Open slide detailBeat · Action
77
The table provides a clear breakdown of adjustments including taxes, D&A, asset impairments, acquisition costs, and share-based compensation.analyze_data
Open slide detailBeat · Action
78
Includes adjustments for foreign exchange rates, divestitures, and discontinuations.analyze_data
Open slide detailBeat · Action
79
The table breaks down revenue adjustments by segment, including foreign exchange impacts and divestitures/discontinuations.analyze_data
Open slide detailBeat · Action
80
The table is split into two main sections: calculation of organic revenue for current periods and calculation of organic revenue for prior periods, followed by analyze_data
Open slide detailBeat · Action
81
The table adjusts reported revenue for exchange rates and divestitures/discontinuations to arrive at organic revenue.analyze_data
Open slide detailBeat · Action
82
Standard financial reconciliation table for non-GAAP metrics.analyze_data
Open slide detailBeat · Action
83
The table provides a detailed breakdown of adjustments including impairments, restructuring, and other non-GAAP items.analyze_data
Open slide detailBeat · Action
84
The right-hand sidebar acts as a navigation menu for the appendix section.appendix
Open slide detailBeat · Action
85
This slide serves as a glossary/disclosure for non-GAAP metrics, with a navigation sidebar listing other metrics.appendix
Open slide detailBeat · Action
86
The right-hand sidebar acts as a navigation menu for the appendix section.appendix
Open slide detailBeat · Action
88
This slide serves as a glossary for financial metrics, likely part of a larger investor presentation.appendix
Open slide detailBeat · Action
89
The right-hand sidebar acts as a navigation menu for the appendix section.appendix
Open slide detailBeat · Action
90
This slide serves as a glossary/methodology reference for financial reporting.appendix
Open slide detailBeat · Action
91
The slide features a sidebar navigation menu listing various non-GAAP metrics, with the current section 'Adjusted Cash Flows from Operations' and 'Bausch Pharmaappendix
Open slide detailBeat · Action